Drugs / VMA-1001
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07304089 Comparator | Feb 2026 → Mar 2027 expected | dystonic disorder | Vima Therapeutics | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VMA-1001 | “VIM0423 is a combination drug product containing two active ingredients (VMA-1001 and VMA-1002)” NCT07304089 ↗ |